Abstract
Mutations in the receptor binding domain region of SARS-CoV-2 have been shown to impact the infectivity, pathogenicity and transmissibility of new variants. Even more worrisome, those mutations have the potential of causing immune escape, undermining the population immunity induced by ongoing mass vaccination programs.
The massive parallel sequencing techniques have taken a lead role in the detection strategies of the new variants. Nevertheless, they are still cumbersome and labour-demanding. As a matter of fact, there is an urgent need for novel strategies and techniques aimed at the surveillance of the active emergence and spread of the variants of concern.
Two PCRs were designed to target the binding domain region, spanning residues N417 through N501 of the Spike protein. Furthermore, very rapid, affordable and straightforward Denaturing High-Performance Liquid Chromatography screening was set up. The screening consisted of mixing the unknown sample with a standard sample of a known sequence, denaturing at high temperature for two minutes, renaturing for 15 minutes followed by a 2-minute run using the WAVE® DHPLC system to detect the heteroduplexes which invariably originate whenever the unknown sample has a nucleotide difference with respect to the standard used. The workflow was able to readily detect new variants including the P.1 and the B.1.585 strains at a very affordable cost. This approach has the potential of greatly expediting surveillance of the SARS-CoV-2 variants.
Competing Interest Statement
SP is an employee of ADS Biotec. ADS Biotec retains proprietary technologies to carry out DHPLC. SP supported the study by providing technical support. No financial support was provided by ADS Biotec which could have inappropriately influenced the conclusion of the study. There are no patents products in development or marketed products to declare. All authors are committed to adhere to the Journal policies on sharing data and materials.
Funding Statement
Partial financial support was received from AUSL Romagna under the protocol code COVdPCR
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of AUSL Romagna under the protocol code -COVdPCR- of 07/02/2020. (include appropriate approvals or waivers)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available at request from the Authors